The Search for Surrogate Endpoints in Trials in Diffuse Large B-Cell Lymphoma: The Surrogate Endpoints for Aggressive Lymphoma Project

Daniel J Sargent; Qian Shi; Christopher R Flowers; Norbert Schmitz; Thomas M Habermann; Jocelyne Flament; Tommy Fu; Bertrand Coiffier; SEAL group

doi:10.1634/theoncologist.2017-0177

The Search for Surrogate Endpoints in Trials in Diffuse Large B-Cell Lymphoma: The Surrogate Endpoints for Aggressive Lymphoma Project

Oncologist. 2017 Dec;22(12):1415-1418. doi: 10.1634/theoncologist.2017-0177. Epub 2017 Aug 10.

Authors

Daniel J Sargent¹, Qian Shi², Christopher R Flowers³, Norbert Schmitz⁴, Thomas M Habermann⁵, Jocelyne Flament⁶, Tommy Fu⁷, Bertrand Coiffier⁸; SEAL group

Affiliations

¹ Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota, USA.
² Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota, USA shi.qian2@mayo.edu.
³ Department of Bone Marrow and Stem Cell Transplantation, Winship Cancer Institute of Emory University, Atlanta, Georgia, USA.
⁴ Department of Internal Medicine A, Hematology, Oncology and Pneumonology, University Hospital Muenster, Muenster, Germany.
⁵ Department of Hematology, Mayo Clinic, Rochester, Minnesota, USA.
⁶ Celgene Corporation, Boudry, Switzerland.
⁷ Celgene Corporation, Summit, New Jersey, USA.
⁸ Department of Hematology, Centre Hospitalier Lyon-Sud, Pierre-Benite, France.

Abstract

This commentary describes the progress of the SEAL [Surrogate Endpoints for Aggressive Lymphoma] research group and invites collaboration in sharing data to continue building a large database of individual patient data from multiple clinical trials in DLBCL.

Keywords: Biomarkers; Clinical trials; Diffuse large B‐cell lymphoma; Individual patient data; Meta‐database; Surrogate endpoints.

MeSH terms

Biomarkers / analysis*
Clinical Trials as Topic*
Endpoint Determination
Humans
Lymphoma, Large B-Cell, Diffuse / metabolism
Lymphoma, Large B-Cell, Diffuse / mortality*
Lymphoma, Large B-Cell, Diffuse / therapy
Meta-Analysis as Topic
Survival Rate
Treatment Outcome

Substances

Biomarkers

Grants and funding

U10 CA180820/CA/NCI NIH HHS/United States